Skip to main content
Equibles
APYX logo

APYX · Apyx Medical Corp · Webcasts, Transcripts & Audio

Track APYX — free

Use APYX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research APYX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.61 +0.11 (+4.40%) Q1 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$105.31M
Shares
42.12M
Volume · Oct 28 34.76K Avg daily vol (3M) 141.88K

Apyx Medical Corp Webcasts

Earnings calls, investor updates, investor days and conferences for Apyx Medical Corp (APYX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-08-06
Apyx Medical Corp (APYX) Q2 2026 Earnings Call
Revenue
$13.88M
▲ 22.1% YoY
Gross margin
63.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Apyx Medical Corp (APYX) Q1 2026 Earnings Call Transcript
Confident tone AYON body contouring system launch GLP-1 demand tailwind Surgical Aesthetics revenue growth
Revenue
$12.49M
▲ 32.4% YoY
Gross margin
63.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-10
Apyx Medical Corp (APYX) Q4 2025 Earnings Call Transcript
Confident tone AYON body contouring system launch and demand Revenue growth and quarterly results Financial health, cash runway and profitability path
Revenue
$19.16M*
▲ 34.7% YoY
Gross margin
62.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Apyx Medical Corp (APYX) Q3 2025 Earnings Call Transcript
Confident tone AYON Body Contouring System Launch Revenue Growth and Financial Performance GLP-1 Market Opportunity
Revenue
$12.88M
▲ 12.1% YoY
Gross margin
64.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Apyx Medical Corp (APYX) Q2 2025 Earnings Call Transcript
Confident tone AYON System Launch China Expansion Renuvion / Advanced Energy
Revenue
$11.37M
▼ 6.4% YoY
Gross margin
62.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Apyx Medical Corp (APYX) Q1 2025 Earnings Call Transcript
Positive tone AYON platform launch Renuvion product performance Cost restructuring and cash management
Revenue
$9.43M
▼ 7.9% YoY
Gross margin
60.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Apyx Medical Corp (APYX) Q4 2024 Earnings Call Transcript
Positive tone GLP-1 Tailwind & Surgical Aesthetics Opportunity Advanced Energy Segment Performance Renuvion System Positioning
Revenue
$14.22M*
▼ 3% YoY
Gross margin
63.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Apyx Medical Corp (APYX) Q3 2024 Earnings Call Transcript
Positive tone Ayon next-generation platform Operating expense reduction plan Restructuring and workforce reduction
Revenue
$11.49M
▼ 4.1% YoY
Gross margin
60.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Apyx Medical Corp (APYX) Q2 2024 Earnings Call Transcript
Balanced tone Guidance and H2 outlook Clinical evidence and Renuvion technology Handpiece growth
Revenue
$12.15M
▼ 10.5% YoY
Diluted EPS
$-0.19
Gross margin
61.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Apyx Medical Corp (APYX) Q1 2024 Earnings Call Transcript
Cautious tone Advanced Energy Revenue Decline Renuvion Clinical Evidence and Clearances OEM Segment Growth
Revenue
$10.24M
▼ 15.6% YoY
Diluted EPS
$-0.22
Gross margin
58.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Apyx Medical Corp (APYX) Q4 2023 Earnings Call Transcript
Positive tone Advanced Energy Revenue Growth Capital Equipment Headwinds Renuvion Micro Handpiece Launch
Revenue
$14.66M*
▲ 16.3% YoY
Gross margin
60.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Apyx Medical Corp (APYX) Q3 2023 Earnings Call Transcript
Revenue
$11.98M
▲ 31.4% YoY
Diluted EPS
$-0.13
Gross margin
66.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Apyx Medical Corp (APYX) Q2 2023 Earnings Call Transcript
Revenue
$13.57M
▲ 31.8% YoY
Diluted EPS
$-0.03
Gross margin
68.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Apyx Medical Corp (APYX) Q1 2023 Earnings Call Transcript
Revenue
$12.14M
▼ 2.8% YoY
Diluted EPS
$-0.10
Gross margin
62.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Apyx Medical Corp (APYX) Q4 2022 Earnings Call Transcript
Revenue
$12.61M*
▼ 25% YoY
Gross margin
65.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Apyx Medical Corp (APYX) Q3 2022 Earnings Call Transcript
Revenue
$9.11M
▼ 23% YoY
Diluted EPS
$-0.17
Gross margin
63.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Apyx Medical Corp (APYX) Q2 2022 Earnings Call Transcript
Revenue
$10.29M
▼ 8.3% YoY
Diluted EPS
$-0.16
Gross margin
67.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Apyx Medical Corp (APYX) Q1 2022 Earnings Call Transcript
Revenue
$12.49M
▲ 44.6% YoY
Diluted EPS
$-0.17
Gross margin
65.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Apyx Medical Corp (APYX) Q4 2021 Earnings Call Transcript
Revenue
$16.82M*
▲ 46.8% YoY
Gross margin
72.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Apyx Medical Corp (APYX) Q3 2021 Earnings Call Transcript
Revenue
$11.83M
▲ 70.1% YoY
Diluted EPS
$-0.12
Gross margin
68.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Apyx Medical Corp (APYX) Q2 2021 Earnings Call Transcript
Revenue
$11.22M
▲ 161.3% YoY
Diluted EPS
$-0.12
Gross margin
67.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Apyx Medical Corp (APYX) Q1 2021 Earnings Call Transcript
Revenue
$8.64M
▲ 72.9% YoY
Diluted EPS
$-0.14
Gross margin
67.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-13
Apyx Medical Corp (APYX) Q4 2020 Earnings Call Transcript
Revenue
$11.46M*
▲ 36.8% YoY
Gross margin
67.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Apyx Medical Corp (APYX) Q3 2020 Earnings Call Transcript
Revenue
$6.95M
▼ 8.2% YoY
Diluted EPS
$-0.11
Gross margin
67.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Date not confirmed
Apyx Medical Corp (APYX) Q2 2020 Earnings Call Transcript
Revenue
$4.30M
▼ 35.4% YoY
Diluted EPS
$-0.14
Gross margin
48.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Apyx Medical Corp (APYX) Q1 2020 Earnings Call Transcript
Revenue
$5.00M
▼ 11.2% YoY
Gross margin
59.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-16
Apyx Medical Corp (APYX) Q4 2019 Earnings Call
Revenue
$8.38M
▲ 43.4% YoY
Gross margin
66.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 719135 CUSIP 03837C106 13F (30d) 5 filings 5 filers Visit website Investor relations